COMPACT
16 evidence topics · 5 sources
Objective
Location and study date
Trial locations and global end date
| Field | Reported value |
|---|---|
| Planned region | “Argentina” |
| Planned region | “Australia” |
| Planned region | “Canada” |
| Planned region | “European Union” |
| Planned region | “United States” |
| Global end of trial | “2015-10-12” |
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using HAE attack frequency as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Population | Participants |
|---|---|
| Whole trial | “100” |
Actual randomization
| Population | Participants |
|---|---|
| Randomized | “90”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Study completion
| Disposition | Participants |
|---|---|
| Completed | “79”View highlighted excerpt for this quote |
Baseline characteristics
Baseline age
| Characteristic | Reported value |
|---|---|
| Median age, years (range) | “40 (12 to 72)” |
Efficacy results
Monthly attack-rate differences versus placebo
| Regimen | Mean difference, attacks per month |
|---|---|
| 40 IU/kg twice weekly | “-2.42”View highlighted excerpt for this quote |
| 60 IU/kg twice weekly | “-3.51”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
Post hoc HRQoL analysis: instruments and timing
“Post hoc analysis of data from the placebo-controlled, crossover phase III COMPACT study” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HRQoL assessments at week 14 (last visit) included the European Quality of Life-5 Dimensions Questionnaire (EQ-5D-3L), the Hospital Anxiety and Depression Scale (HADS), the Work Productivity and Activity Impairment Questionnaire (WPAI), and the Treatment Satisfaction Questionnaire for Medication (TSQM).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HRQoL during subcutaneous C1-INH compared with placebo
“Compared with placebo (on-demand treatment alone), treatment with twice weekly C1-INH(SC) (both doses combined) was associated with better EQ-5D visual analog scale general health, less HADS anxiety, less WPAI presenteeism, work productivity loss, and activity impairment, and greater TSQM effectiveness and overall treatment satisfaction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For each HRQoL measure, a greater proportion of patients had a clinically meaningful improvement during C1-INH(SC) treatment compared with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Study limitations
Summary
The crossover trial randomized 90 participants against a planned enrollment of 100, and 79 participants completed it. Each participant received active treatment and placebo in sequence, and efficacy was evaluated “for the last 14 weeks of each treatment period” of the 32-week study, so period and carryover effects can influence the estimates. The efficacy results reported for this trial are mean differences from placebo in monthly attack rate (-2.42 attacks per month with 40 IU/kg and -3.51 with 60 IU/kg twice weekly), which are not directly comparable with absolute attack rates reported for parallel-group designs. No health-related quality of life result for this trial was identified. The trial enrolled participants aged 12 years or older, with a median age of 40 years (range, 12 to 72). Subcutaneous C1 inhibitor was compared with placebo only, so comparison with other prophylactic agents relies on cross-trial comparison.